Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

6.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
6.2K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.9K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.9K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

4.5K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.5K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.8K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

6.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age-related efficacy of aspirin in secondary prevention of coronary artery disease: START-ANTIPLATELET registry and meta-analysis of randomized trials.

The American journal of medicine·2026
Same author

Significance of 8-iso-PGF<sub>2α</sub> in cardiovascular diseases.

American heart journal plus : cardiology research and practice·2026
Same author

GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies.

Diabetes research and clinical practice·2026
Same author

Circulating S100A8/A9 drives faster platelet COX-1 recovery via MRP4, impairing the duration of aspirin response.

Blood advances·2026
Same author

Circulating S100A8/A9 drives faster platelet COX-1 recovery via MRP4, impairing the duration of aspirin response.

Blood advances·2025
Same author

Soluble platelet activation markers in coronary artery disease: a step toward precision thrombosis risk assessment?

Journal of thrombosis and haemostasis : JTH·2025

Related Experiment Video

Updated: Apr 12, 2026

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies
07:06

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies

Published on: January 10, 2025

1.4K

Platelets and diabetes mellitus.

Francesca Santilli1, Paola Simeone1, Rossella Liani1

  • 1Internal Medicine and Center of Excellence on Aging, "G. D'Annunzio" University of Chieti, Italy.

Prostaglandins & Other Lipid Mediators
|May 20, 2015
PubMed
Summary

Platelet activation in type 2 diabetes mellitus (T2DM) drives atherothrombosis. Understanding metabolic derangements and platelet inflammatory roles is key to developing targeted therapies for diabetic cardiovascular complications.

Keywords:
ASA responsivenessDiabetes mellitusOxidative stressPlatelet activationPlatelet turnoverPlatelet-derived inflammatory proteins

More Related Videos

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

12.1K
Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature
05:54

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature

Published on: January 24, 2025

840

Related Experiment Videos

Last Updated: Apr 12, 2026

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies
07:06

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies

Published on: January 10, 2025

1.4K
Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

12.1K
Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature
05:54

Quantification of Diabetes-induced Adherent Leukocytes in Retinal Vasculature

Published on: January 24, 2025

840

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Hematology

Background:

  • Platelet activation is central to atherothrombosis in type 2 diabetes mellitus (T2DM).
  • Impaired glucose metabolism, even in early stages, increases platelet activation and thromboxane (TX) biosynthesis.
  • Platelets act as mediators, linking metabolic dysfunction to vascular injury in T2DM.

Purpose of the Study:

  • To review key pathophysiological aspects of platelet activation in T2DM.
  • To explore the role of hyperglycemia, glycemic variability, and insulin resistance in platelet activation.
  • To examine platelet-derived inflammatory mediators and their impact on vascular inflammation.
  • To discuss mechanisms of reduced aspirin (ASA) efficacy and patient stratification for antiplatelet strategies.

Main Methods:

  • Critical review of existing literature on platelet function in T2DM.
  • Analysis of pathophysiological mechanisms linking metabolic derangements to platelet activation.
  • Evaluation of inflammatory mediators released by activated platelets.
  • Assessment of factors influencing antiplatelet therapy effectiveness in diabetic patients.

Main Results:

  • Hyperglycemia, glycemic variability, and insulin resistance are significant determinants of platelet activation in T2DM.
  • Platelet-derived mediators (e.g., sCD40L, sCD36, DKK1, sRAGE) amplify inflammation, extending platelet roles beyond hemostasis.
  • Suboptimal antithrombotic protection by aspirin (ASA) may occur in T2DM patients.
  • Metabolic phenotype can guide the stratification of patients for tailored antiplatelet strategies.

Conclusions:

  • Platelet activation and inflammation are critical in T2DM-associated atherothrombosis.
  • Understanding these mechanisms can inform the development of novel, mechanism-based therapies.
  • Personalized antiplatelet strategies based on metabolic phenotype may improve outcomes in diabetic patients.